Reference : CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in eld...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/10062
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de I'Adulte
English
Bonnet, Christophe mailto [Université de Liège - ULg > Département des sciences cliniques > Hématologie - Oncologie médicale]
Fillet, Georges mailto [Université de Liège - ULg > Département des sciences cliniques > Hématologie - Oncologie médicale]
Mounier, N. [> > > >]
Ganem, G. [> > > >]
Molina, T. J. [> > > >]
Thieblemont, C. [> > > >]
Ferme, C. [> > > >]
Quesnel, B. [> > > >]
Brassiene, Christine [Centre Hospitalier Universitaire de Liège - CHU > > HOSPITALISATION - GASTRO & NEPHROLOGIE (SN +4B) >]
Gisselbrecht, C. [> > > >]
Tilly, H. [> > > >]
Reyes, F. [> > > >]
1-Mar-2007
Journal of Clinical Oncology
Amer Soc Clinical Oncology
25
7
787-792
Yes (verified by ORBi)
International
0732-183X
1527-7755
Alexandria
[en] Purpose Chemoradiotherapy has been considered standard treatment for patients with limited-stage aggressive lymphoma on the basis of trials conducted before the introduction of the International Prognostic Index. To evaluate this approach in elderly patients with low-risk localized lymphoma, we conducted a trial comparing chemoradiotherapy with chemotherapy alone. Patients and Methods Previously untreated patients older than 60 years with localized stage I or II histologically aggressive lymphoma and no adverse prognostic factors of the International Prognostic Index were randomly assigned to receive either four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (299 patients) or chemotherapy alone with four cycles of CHOP (277 patients). Results With a median follow-up time of 7 years, event-free and overall survival did not differ between the two treatment groups (P =.6 and P =.5, respectively). The 5-year estimates of event-free survival were 61% for patients receiving chemotherapy alone and 64% for patients receiving CHOP plus radiotherapy; the 5-year estimates of overall survival were 72% and 68%, respectively. In a multivariate analysis, overall survival was affected by stage II disease (P <.001) and male sex (P =.03). Conclusion In this large prospective study, CHOP plus radiotherapy did not provide any advantage over CHOP alone for the treatment of low-risk localized aggressive lymphoma in elderly patients.
http://hdl.handle.net/2268/10062
10.1200/JCO.2006.07.0722

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
217.pdfPublisher postprint128.72 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.